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Abstract
Chronic liver insult leads to fibrosis, which often ends up causing cirrhosis and
most of the time that progresses into hepatic neoplasms (early Hepatocellular
carcinoma; HCC). HCC is the fifth most common cancer, and the third cause of cancerrelated deaths. Chemotherapy is the most common treatment of cancer patients. HCC
is however, chemo-resistant, and the side-effects of chemotherapy are typically
exhausting to the patient. Sorafenib is the only anti-HCC drug approved by the U.S
Food and Drug Administration. It is a multikinase inhibitor that blocks tumor cells
proliferation and angiogenesis. Although sorafenib is successful treating early and mid
HCC lesions, it is not efficient in advanced HCC cases. Safranal, a major biomolecule
of saffron “stigmas of the flowers of Crocus sativus L.”, is known for its anti-oxidant,
proapoptotic and anti-inflammatory effects against different cancer types. Compared
with monotherapy, combination therapy (safranal + sorafenib) targeting multiple
signaling pathways offered a better treatment alternative potentially abolishing
resistance, feedback activation, and compensatory activation of survival pathways.
This study investigated the therapeutic effect of safranal on DEN-induced hepatic
neoplasms, in vivo, using male Wistar rats. Safranal was found to be involved in cell
cycle arrest particularly at G2/M phase, and to induce the intrinsic, mitochondrial,
apoptotic pathway leading to cell death. This study highlights safranal’s therapeutic
potential against HCC and introduces it as a novel natural therapeutic and adjuvant
agent against HCC.

Keywords: Hepatocellular carcinoma, safranal, sorafenib, apoptosis, cell cycle
arrest.
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)Title and Abstract (in Arabic

تقييم اآلثار العالجية للسافرانال ضد سرطان الكبد المستحث كيميائيا في الجرذان
الملخص

تؤدي إصابة الكبد المزمنة إلى تليفه ،والذي غالبا ً ما يؤدي إلى تشمع الكبد و في معظم
الوقت يتطور إلى أورام كبدية (سرطان الكبد) .سرطان الكبد هو خامس نوع من السرطانات
األكثر شيوعا ً ،والسبب الثالث للوفيات المرتبطة بالسرطان .العالج الكيميائي هو األكثر شيوعا ً
لعالج مرضى السرطان ،ومع ذلك ،فإن سرطان الخاليا الكبدية يقاوم العالج الكيميائي ،باإلضافة
إلى أن اآلثار الجانبية للعالج الكيميائي عادة ما تكون مرهقة للمريض .سورافينيب هو الدواء
الوحيد المرخص من قبل إدارة الغذاء والدواء األمريكية المستخدم في عالج سرطان الكبد .وهو
يمنع انتشار الخاليا الورمية وتولد األوعية الدموية الجديدة .على الرغم من نجاح دواء
السورافينيب في عالج اآلفات المبكرة والمتوسطة من سرطان الخاليا الكبدية ،إال أنه غير فعال
في حاالت سرطان الكبد المتقدمة .سافرانال ،هو جزيء حيوي رئيسي من نبات الزعفران
معروف بآثاره المضادة لألكسدة والمضادة لاللتهاب ضد أنواع مختلفة من السرطان .مقارنة
بالعالج األحادي  ،العالج المركب (سورافينيب  +سافرانال) الذي يستهدف المسارات المتعددة
خيارا أفضل للعالج عن طريق توفير طريقة إلبطال المقاومة ،وتفعيل ردود الفعل
للسرطان قدم
ً
من الجسم .هذه الدراسة بحثت تأثير السافرانال العالجي على سرطان الكبد الناتج عن حقن مركب
 Diethylnitrosamineفي الجرذان من نوع  .Wistarنتائج البحث تشير أن السافرانال يؤثر
في اعتقال دورة الخلية خصوصا ً في مرحلة ( G2/Mطور النمو الثاني و طور االنقسام) ،وأيضا ً
يحث على موت الخلية المبرمج في المسار الداخلي ،مما يؤدي إلى موت الخاليا السرطانية .هذه
الدراسة تسلط الضوء على أهمية السافرانال ضد سرطان الكبد ،كعامل عالجي طبيعي ومساعد.

مفاهيم البحث الرئيسية :سرطان الكبد ،سافرانال ،سورافينيب ،موت الخلية المبرمج ،اعتقال
دورة حياة الخلية.
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Chapter 1: Introduction
1.1 Cancer
Cancer starts with a single defected cell that grows and multiplies into a group
of cancerous cells. This group of cells, tumor, needs to go through several important
hallmarks to survive and spread. The normal cell goes through complex mechanisms
of reproduction, growth, and death with the help of signals and enzymes to maintain a
normal tissue or organ size. Cancer cells, on the other hand, keep proliferation and
replication signals on, skip growth suppressors and cell death, invade neighboring
tissue and make new blood vessels to survive (Figure 1; Hanahan & Weinberg, 2011).
There are several factors that could lead to cancer development such as smoking,
radiation, and viruses, thus, a healthy lifestyle is highly recommended especially for
those with a family history of cancer (Martin & McFerran, 2017). The International
Agency for Research on Cancer reported 14.1 million cases of cancer and 8.2 million
deaths worldwide in 2012 (Ferlay et al., 2015). The number of deaths increased to 8.8
million in 2015 advancing cancer to be the second cause of death worldwide (World
Health Organization, 2018). In the United Arab Emirates (UAE), cancer is the third
cause of death, and according to the UAE Ministry of Health – Abu Dhabi, there are
around 500 cancer deaths every year (Tadmouri & Al-Sharhan, 2004).
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Figure 1: Hallmarks of cancer (Hanahan & Weinberg, 2011)

1.2 The Liver
The liver is the largest internal organ of the body, which lies in the top right
abdominal cavity and weighs around 1500 gm. It secretes bile; which helps digesting
fat and neutralizing stomach acid. It is also, where carbohydrates, proteins, and fats
are metabolized. Liver also helps maintaining blood sugar and producing blood
proteins essential for the detoxification process. Different types of cells make up the
liver tissue, with hepatocytes being the most represented cell type where they occupy
80% of the liver (Kmieć, 2001). Hepatocytes form sheets that face the blood veins in
the liver, they synthesize, degrade and store many substances, including glycogen.
Important vitamins are stored in the liver such as vitamins A, D, K, and B12 (Cammack
et al., 2006c, 2006b, 2006a; Concise Medical Dictionary, 2010).

3
1.2.1 Hepatocellular Carcinoma
There are different types of liver cancer; intrahepatic cholangiocarcinoma and
hepatoblastoma, but the most common type is hepatocellular carcinoma (HCC).
Repeated liver injury or disease causes acute inflammation in the liver, which is
usually reversible, then if not treated progresses to fibrosis and cirrhosis (irreversible),
and finally hepatic neoplasms (Ramakrishna et al., 2013). HCC is the fifth most
common cancer type and the third cause of cancer-related deaths worldwide (Zhang et
al., 2014). In the UAE, liver cancer is the fourth cause of death related to cancer in
both men and women (Figure 2; Department of Health - Abu Dhabi, 2016). The
mortality rate has increased with an average of only 5-year survival. Among known
HCC risk factors, hepatitis C and B viral infections and alcohol consumption are the
most common. However, 15 – 50% of HCC cases emerge without known causes (Zhou
et al., 2016). Different chemotherapeutic drugs are used to treat HCC including
fluorouracil, cisplatin, doxorubicin, paclitaxel and mitomycin. Side effects, caused by
the non-selective cytotoxicity of these drugs, remain a major challenge (Subramaniam
et al., 2013). Increasing numbers of patients opt for surgical intervention. Removing
the tumor and liver transplant are most common in early stages of HCC with 50%
survival chances, however, most of later-staged patients have limited treatment options
(Pang & Lam, 2015).
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Figure 2: Top four main causes of death related to cancer in the United Arab
Emirates – Abu Dhabi in men and women (Department of Health - Abu Dhabi, 2016)

1.3 Sorafenib
Sorafenib, a multikinase inhibitor, is known to block tumor proliferation, and
inhibit angiogenesis. It is also, the first U.S. Food and Drug Administration (FDA)
approved HCC therapy (Finn et al., 2013; Subramaniam et al., 2013). However,
survival rates with sorafenib are barely extended by 5 – 10 months compared to
placebo (El-Serag, 2017). The common side effects of sorafenib are skin toxicity,
diarrhea, hypertension, and bleeding (Crissien & Frenette, 2014). Therefore, exploring
other treatment options is well justified in an attempt to provide an efficient treatment
or adjuvant anti-HCC drug with minimum side effects.
1.4 Plants in Medicine
Plants have always been the first source of treatment throughout history. As a
main source of human food, plants are generally considered to be safe. Thus, plants
have traditionally been used for health promoting purposes (Prinsloo et al., 2018).
Around 50,000 plant species have been exploited as a source of different drugs.
Aspirin from willow bark, quinine from cinchona bark and morphine from the opium
poppy are a few examples.
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Thanks to their broad spectrum benefits that are associated with minimal sideeffects, people are increasingly turning to plants for treatment despite all recent
developments in the field of drug discovery (Rana & Rana, 2014). Nearly 50% of
approved anti-cancer drugs are plant in origins (Veeresham, 2012; Greenwell &
Rahman, 2015).
1.4.1 Plants and Cancer Therapy
Recent studies have shown the beneficial effects of plant extracts in cancer
therapy due to their low side effects, and anti-tumor activities. Modern therapy is also
shifting to plants as boosters for current medicines of chemotherapy, or even for novel
replacements. Investigations showed that plants stimulate the immune system, and
exhibit antibacterial, anti-inflammatory, antioxidant, and anti-cancer effects (Ahmad
et al., 2017).
1.4.1.1 Saffron
Crocus sativus L. from the family Iridaceae has a purple flower with three red
stigmas, called saffron, which is a natural spice and colorant. Saffron is mainly grown
in Iran and Spain. Due to the extreme delicacy needed in harvesting and handling
saffron, it is considered the most expensive “golden” spice. To yield 500 gm of pure
saffron, 70,000 flowers must be handpicked. Saffron contains more than 150 bioactive
ingredients. Crocin, picrocrocin, and safranal are the most common among all those
ingredients. They are responsible for saffron color, taste and odor, respectively.
Saffron has traditionally been used as antidepressant, antispasmodic, decongestant,
and a sedative. It was also used to treat fever, smallpox, and colds (Gohari et al., 2013;
Rezaee & Hosseinzadeh, 2013; Srivastava et al., 2010).
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1.4.1.1.1 Safranal
Safranal, the oily compound of saffron, is the main source for saffron odor.
Safranal is known as an antioxidant and it protects against seizure and has a cytotoxic
effect against cancer cells (Rezaee & Hosseinzadeh, 2013). In neuroblastoma cells,
safranal has been reported to inhibit the growth of malignant cells by inducing
apoptosis (Samarghandian et al., 2014).
1.5 Cancer in Research
Research has helped to understand the molecular mechanisms of cancer and
therefore offering ways to control it. In the lab, in vivo and in vitro methods are
commonly used to investigate and assess different treatment strategies. In vitro setting
is based on assessing different drugs in isolated human cancer cell lines; outside the
living body (Hine & Martin, 2015). The main disadvantage of such approach is that
cultured cancer cells do not mimic the natural environment of a tumor in a living body.
In vivo setting research induces and hence studies tumors in living organisms rather
than in isolated cells (Lackie, 2010). Whole organisms, like rats, mice, and rabbits, are
often used in vivo where natural tumor environment is better assessed. There are
several ways to induce cancer in animals by using chemicals, viruses, gene editing, or
a transplant (Figure 3; Santos et al., 2017).

7

Figure 3: Different methods for inducing cancer in animal models (Santos et al.,
2017)

1.5.1 Diethylnitrosamine
Diethylnitrosamine (DEN) is a widely used chemical for inducing cancer. Nnitroso compounds are known for their mutagenic and carcinogenic properties. In
1956, investigators reported liver carcinogenesis in albino rats fed with a diet
containing dimethylnitrosamine. Then few years later, a sheep died of liver toxicity
after feeding from a meal that was preserved with nitrite. Thus, DEN effect was heavily
studied and was shown to initiate liver injury, and lead to liver fibrosis, cirrhosis, and
finally HCC. DEN can also induce tumor in respiratory tract, kidney, upper digestive
tract, and hematopoietic system (Santos et al., 2017).
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1.6 Objectives of the Study
The aim of this study is to examine safranal’s therapeutic effects against
chemically induced hepatic neoplasms and that involves:
1. Chemical induction of hepatic neoplasms in Wistar rats.
2. Biochemical assessment of liver function.
3. Histopathological examination of liver tissues.
4. Western blotting examination of representative markers.
1.7 Hypothesis
We hypothesize that safranal will have a suppressive effect on DEN-induced
hepatic neoplasms in vivo.
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Chapter 2: Methodology
2.1 In vivo Study
2.1.1 Animals
Male Wistar rats, weighing around 160 gm, were used in this study. Rats were
provided by the animal research facility at the College of Medicine and Health
Sciences, UAEU. Rats were housed under a 12-hour light/dark cycle at 24 – 26°C.
They were maintained on a standard laboratory animal diet with food and water ad
libitum. Animal ethics form has been submitted and approved by the Animal Research
Ethics Committee of the College of Medicine and Health Sciences, UAEU (Approval
No. A8-15).
2.1.2 Experimental Design
A modified version of the protocol described by DePeralta et al. (2016) and
Schiffer et al. (2005) was used here to establish the hepatocarcinogenesis model.
Animals were divided into five groups, each group has eight animals labelled as
follows: control phosphate buffered saline (PBS), HCC, HCC + sorafenib, HCC +
safranal, and HCC + safranal + sorafenib (Figure 4).
On the first 15 weeks, control PBS group was treated with 1x PBS, whereas
the experimental groups were given an intraperitoneal injection (IP) of 50 mg/kg DEN
(Sigma Aldrich), once a week. DEN was diluted with 1x PBS. Followed by a oneweek break (week 16), the next three weeks (weeks 17 to 19) treatment started. All
drugs were administrated by oral gavage. All doses were chosen according to literature
(Alsaied et al., 2014; Karafakıoğlu et al., 2017). For HCC + sorafenib group, the drug
(Carbosynth Limited) was administered at a dose of 10 mg/kg, five days a week.

10
For HCC + safranal group, the drug (Sigma Aldrich) was administered at a
dose of 200 mg/kg, five days a week. For HCC + safranal + sorafenib group, the drugs
were administered at a dose of 200 mg/kg safranal + 10 mg/kg sorafenib, five days a
week. Both safranal and sorafenib were diluted with 1x PBS and drops of Tween 80.
Oral LD50 of safranal is 5.53 mL/kg in male rats (Hosseinzadeh et al., 2013).
After 24-hours from last treatment, rats were euthanized by mild diethyl ether
and dissected in equal conditions. Blood and whole liver were collected.

Figure 4: Experimental design
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2.2 Sample Preparation
2.2.1 Blood Samples
Rats were euthanized then blood was collected by decapitation and processed
for later investigation. The blood was collected in collection tubes (BD Vacutainer)
and serum was separated by centrifugation at 1200 × g for 10 minutes. Serums was
collected and flash frozen immediately then stored at -80 °C for further analysis.
2.2.1.1 Biochemical Analysis
Alanine Transaminase (ALT), and Aspartate Aminotransferase (AST) assays
were performed using commercial kits (Abcam), according to the protocol provided.
ALT and AST activities were measured spectrophotometrically using Epoch by
BioTek.
2.2.2 Liver Samples
Part of the liver was immediately flash frozen in liquid nitrogen then stored at
-80°C for further analysis. The other part was kept in 10% neutral buffered formalin
at room temperature for histology.
2.2.2.1 Histopathological Examination
Liver sample specimens were fixed in 10% neutral buffered formalin,
dehydrated in a series of graded ethanol, embedded in paraffin blocks, and cut into 3
µm-thick sections. To detect histopathological changes, sections were stained with
hematoxylin and eosin (H&E), and reticulin stain kit according to the protocol
provided (Abcam), then examined under light microscope (Ozkececi et al., 2016).
Blinded examination of tissue samples was done by a pathologist from Tawam
Hospital – UAE.
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2.2.2.2 Western Blotting
One hundredth gm (10 mg) liver was homogenized using 200 µl RIPA buffer
(Sigma Aldrich) mixed with 2 µl protease inhibitor and 2 µl phosphatase inhibitor
(Sigma Aldrich), and centrifuged at 4°C, 15,000 rpm for 15 minutes. Whole cell lysate
was taken and stored at -80°C. Protein concentration was measured by Pierce BCA
Protein Assay Kit with Promega GloMax Discover. A total of 35 µg of protein was
loaded on a sodium dodecyl sulfate–polyacrylamide gel electrophoresis gel. The gel
was then transferred to polyvinylidene difluoride membrane. The membrane was then
blocked with 5% BSA in TBST for one hour at room temperature. Membranes were
incubated with anti-Proliferating Cell Nuclear Antigen (PCNA), anti-PolyADP-ribose
Polymerase (PARP), anti-caspase-3 (Cell Signaling Technology Inc.), anti-caspase-9
(Novus Biologicals), anti-Bax, anti-Bcl-2 (Santa Cruz), anti-Cdk1, anti-Cyclin B1,
anti-Cdc25B (Cell Signaling Technology Inc.) over night at 4°C, then with HRP
conjugated secondary, anti-mouse or anti-rabbit, antibody (Cell Signaling Technology
Inc.) for one hour at room temperature. All primary and secondary antibodies were
diluted in 5% BSA in TBST. Blots were incubated in WesternSure PREMIUM
Chemiluminescent Substrate for antibodies’ detection. Signal was visualized using
Bio-Rad ChemiDoc XRS+ System. Band density was measured using ImageJ (Amin
et al., 2011). Total protein was used as a loading control and stained using SYPRO
Ruby protein gel stain according to the protocol provided (Thermo Fisher Scientific)
(Aldridge et al., 2008; Hu et al., 2016).
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2.2.2.2.1 Total Protein as a Loading Control
Due to technical reasons, total protein was used in this study as the loading
control instead of the other common markers like GAPDH, β-tubulin, and β-actin. A
study published in 2003 used liver samples from normal, cirrhotic, and HCC tissues to
inspect the housekeeping genes. Ten internal controls were used, and their expressions
were determined using RT-PCR. Results showed that all internal control genes varied
more than a 2-fold, and the commonly used genes like GAPDH and β-actin varied
from 7- to 23-fold, precisely in tumor tissue (Kim & Kim, 2003). Following studies
then tried to find an alternative way for this issue. Total protein, depending on the
amount of total protein rather than a single protein, served as a better control for
colorectal cancer and HCC compared with different common housekeeping proteins.
Also, testing the signal’s linearity with the loading amounts was preserved in total
protein, while in the other housekeeping proteins it was lost (Aldridge et al., 2008; Hu
et al., 2016). Due to technical problems with all common internal controls, I followed
a protocol that was mentioned by Aldridge et al. (2008) and Hu et al. (2016).
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Chapter 3: Results
Several enzymes are released from hepatocytes into the blood and are
measured in the blood serum to test the efficiency of liver function, ALT and AST are
the most common enzymes for testing liver function. The more severe the liver is
damaged, the higher their serum levels get. Together, they are considered the best
markers for liver injury (Liu et al., 2012). In addition to serum, the whole liver tissues
were collected and properly stored for further histological and immunoblotting
analyses. In histological examination, liver tissues were processed and stained for final
imaging using the microscope (Martin, 2015). To detect markers of specific pathways,
selected proteins were targeted using western blotting.
3.1 Biochemical Analysis
As shown in (Table 1), ALT (P < 0.01) and AST levels were elevated in HCC
group as compared to control group, thus indicating liver damage. Treatment with
safranal and with both safranal + sorafenib significantly (P < 0.01) decreased ALT
levels in the treated groups as compared to HCC group. Safranal and the combination
therapy caused a significance decrease (P < 0.05) as compared to sorafenib alone
(HCC + sorafenib).
Table 1: Effect of safranal on serum biochemical markers

Control PBS

HCC

HCC + sorafenib

HCC + safranal

HCC + safranal + sorafenib

ALT

7.44 ± 0.67

14.10 ± 0.15a** 13.42 ± 1.12

10.93 ± 0.29b**,c*

9.22 ± 1.92b**,c*

AST

9.00 ± 0.39

10.18 ± 1.69

7.80 ± 2.02

10.98 ± 0.50

11.14 ± 0.62

Values are expressed as mean ± SEM of six rats per group (n = 6). Activity is
expressed as mU/ml for ALT and AST. Significance was determined using Microsoft
Excel Data Analysis Tool Pack, t-test: two-sample assuming equal variances (a
versus PBS, b versus HCC, c versus HCC + Sorafenib; *P < 0.05, **P < 0.01)
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3.2 Anti-tumorigenic and Anti-proliferative Activities of Safranal on DEN
Induced Rat Liver Tumors
3.2.1 Liver Gross
Control PBS liver shows normal liver structure and color with no macroscopic
lesions. Treatments showed “lesser levels of damaged livers” compared to livers from
HCC group (Figure 5). DEN caused lesions and rough liver surface and caused
abnormality in liver color in HCC animals. Drug treatments of HCC rats restored to
variable degrees the normal liver architecture where lesions were evidently less in
drug-treated groups. Treatments with safranal (HCC + safranal) and with both safranal
and sorafenib (HCC + safranal + sorafenib) reduced lesions comparing to HCC
animals, safranal also dramatically decreased lesions comparing to treatment with
sorafenib alone (HCC + sorafenib) (Figure 6).
HCC

HCC SB

HCC SF

HCC SF SB

PBS

Figure 5: Representative images of livers on week 20 to demonstrate the antitumorigenic effect of safranal (n = 6). Whole liver excised from control rats (PBS),
DEN-induced hepatic neoplasia in rats untreated (HCC group) or treated with
sorafenib (HCC SB), safranal (HCC SF) individually or combined (HCC SF SB)
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Figure 6: Quantitative analysis of number of liver nodules from DEN-induced
hepatic neoplasia in rats untreated (HCC group) or treated with sorafenib (HCC +
SB), safranal (HCC + SF) individually or combined (HCC + SF + SB). Statistical
significance was determined using Microsoft Excel Data Analysis Tool Pack, t-test:
two-sample assuming equal variances (b versus HCC; *P < 0.05, **P < 0.01)

3.2.2 Histology
Light Microscope images of liver sections (Figure 7). The structure of tissues
and cells need to be stained in order to be visible. Cellular components are normally
stained with a different color for proper distinction and analysis. Hematoxylin stains
nucleic acids (nucleus) with blue color. Eosin stains proteins (cytoplasm) with pink
color. The stain reveals plentiful structural and functional information (Fischer et al.,
2008). Normal structure and histology of liver as seen in the control group where the
liver is organized into hexagonally shaped lobules with the central vein at lobular
centers. Hepatocytes are arranged in single-cell thick plates that radiate out from the
central vein. In the animal model that has been developed in this study, macroscopic
nodules were observed in the livers of mainly DEN-induced groups (Figure 5).
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However, microscopic histological examination of livers of rats in DENinduced group showed clear neoplastic changes such as altered hepatocellular foci
(AHF). In the present study, AHF are generally distinguished as delineated areas of
hepatocytes with altered staining properties. Safranal alone or in combination with
sorafenib seem to enhance (P < 0.001) the restoration of the normal architecture of the
liver in DEN-treated groups (Figure 8).

PBS

HCC

HCC SB

HCC SF

HCC SF SB

Figure 7: Representative images of hematoxylin and eosin-stained sections (arrows
point to representative areas of AHF), n = 6. Sections from control rats (PBS), DENinduced hepatic neoplasia in rats untreated (HCC group) or treated with sorafenib
(HCC SB), safranal (HCC SF) individually or combined (HCC SF SB)

18

Figure 8: Quantitative analysis of area of neoplastic foci for histology from DENinduced hepatic neoplasia in rats untreated (HCC group) or treated with sorafenib
(HCC + SB), safranal (HCC + SF) individually or combined (HCC + SF + SB).
Statistical significance was determined using Microsoft Excel Data Analysis Tool
Pack, t-test: two-sample assuming equal variances (b versus HCC; **P < 0.01, ***P
< 0.001)

3.2.3 Reticulin Staining
Light Microscope images of liver sections from all groups (Figure 9). Control
PBS liver shows normal liver morphology and defined reticular fibers. Liver sections
from HCC animals show that DEN has caused reticular fiber breakage indicating
hepatic neoplasia diagnosis. Treatment with safranal (HCC + safranal) and with both
safranal and sorafenib (HCC + safranal + sorafenib) reduced reticular fibers’ breakage
and restored their morphology comparing to HCC group, with a higher improvement
comparing to treatment with sorafenib alone (HCC + sorafenib).
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PBS

HCC

HCC SB

HCC SF

HCC SF SB

Figure 9: Representative images of reticulin-stained sections (arrows point to
reticulin fibers), n = 6. Sections from control rats (PBS), DEN-induced hepatic
neoplasia in rats untreated (HCC group) or treated with sorafenib (HCC SB), safranal
(HCC SF) individually or combined (HCC SF SB)
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3.2.4 Anti-proliferative Effect of Safranal

a versus PBS, b versus HCC; *P < 0.05, **P < 0.01,
***P < 0.001

Figure 10: Safranal inhibits proliferation of induced hepatic neoplasia. (a) Western
blot analysis of the proliferation-related protein (PCNA) on DEN-induced hepatic
neoplasia in rats untreated (HCC group) or treated with sorafenib (HCC SB), safranal
(HCC SF) individually or combined (HCC SF + SB) (b) Each band intensity was
quantified using ImageJ, normalized in relative to the total protein from the liver.
Results are expressed as mean ± S.D for n = 4 animals in each group. Statistical
significance was determined using Microsoft Excel Data Analysis Tool Pack, t-test:
two-sample assuming equal variances

Western blot results and quantification for PCNA (Figure 10) showed that
PCNA was significantly (P < 0.01) increased in DEN induced livers comparing to
controls, while treatment with safranal (P < 0.001) and with both safranal and
sorafenib (P < 0.05) significantly downregulated PCNA. Interestingly, the effect of
safranal was more evident when applied alone compared to its combined
administration with sorafenib, as well as compared to the effect of sorafenib alone.
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3.3 Western Blotting
3.3.1 Effect of Safranal on Cell Cycle Progression

Figure 11: Safranal causes G2/M cell cycle arrest of induced hepatic neoplasia.
Western blot analysis of the cell cycle-related proteins (Cdk1, Cyclin B1, Cdc25B)
on DEN-induced hepatic neoplasia in rats untreated (HCC group) or treated with
sorafenib (HCC SB), safranal (HCC SF) individually or combined (HCC SF + SB)

a versus PBS, b versus HCC; **P < 0.01, ***P < 0.001

a versus PBS, b versus HCC; *P < 0.05, ***P < 0.001

a versus PBS, b versus HCC; *P < 0.05, **P < 0.01,
***P < 0.001

Figure 12: Quantification of proteins of G2/M cell cycle arrest of induced hepatic
neoplasia. Each band intensity was quantified using ImageJ, normalized in relative to
the total protein from the liver. Results are expressed as mean ± S.D for n = 4
animals in each group. Statistical significance was determined using Microsoft Excel
Data Analysis Tool Pack, t-test: two-sample assuming equal variances
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To study the pathway responsible for safranal mediated cell cycle effect in
DEN-induced rat liver neoplasia, the expression levels of cell cycle-related proteins
were examined. Cdk1, cyclin B1, Cdc25B western blot results (Figure 11) showed that
they are significantly (P < 0.01, P < 0.01, P < 0.05, respectively) increased in HCC
animals as compared to control animals. Treatment in (HCC + safranal) and (HCC +
safranal + sorafenib) groups significantly decreased their levels (P < 0.001) comparing
to HCC animals. Treatment with safranal (HCC + safranal) and the combination drug
(HCC + safranal + sorafenib) showed a greater decrease than treatment with sorafenib
alone (HCC + sorafenib) (Figure 12). It is possible then that safranal may sensitize
hepatic cells to sorafenib’s effect by further decreasing the expression of cell cyclerelated proteins in the co-treated group. These results suggest that safranal causes
G2/M cell cycle arrest of drug-treated hepatic cells.
3.3.2 Effect of Safranal on Apoptosis

Figure 13: Safranal induces intrinsic apoptosis of induced hepatic neoplasia. Western
blot analysis of the intrinsic apoptosis-related proteins (Bcl-2, Bax, Pro-Caspase-9,
Pro-Caspase-3, PARP) on DEN-induced hepatic neoplasia in rats untreated (HCC
group) or treated with sorafenib (HCC SB), safranal (HCC SF) individually or
combined (HCC SF + SB)
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b versus HCC; *P < 0.05

a versus PBS, b versus HCC; *P < 0.05, ***P < 0.001

a versus PBS, b versus HCC; *P < 0.05

Figure 14: Quantification of Bax, Bcl-2, Bax/Bcl ratio. Each band intensity was
quantified using ImageJ, normalized in relative to the total protein from the liver.
Results are expressed as mean ± S.D for n = 4 animals in each group. Statistical
significance was determined using Microsoft Excel Data Analysis Tool Pack, t-test:
two-sample assuming equal variances
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a versus PBS, b versus HCC; *P < 0.05, **P < 0.01

a versus PBS, b versus HCC; *P < 0.05, **P < 0.01, ***P < 0.001

a versus PBS, b versus HCC, c versus HCC + SB; *P < 0.05,
**P < 0.01, ***P < 0.001

Figure 15: Quantification of Pro-Caspase-9, Pro-Caspase-3, PARP. Each band
intensity was quantified using ImageJ, normalized in relative to the total protein from
the liver. Results are expressed as mean ± S.D for n = 4 animals in each group.
Statistical significance was determined using Microsoft Excel Data Analysis Tool
Pack, t-test: two-sample assuming equal variances
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To study the pathway responsible for safranal mediated apoptosis in DENinduced rat liver tumor cells, the expression levels of apoptosis-related proteins were
examined. The results showed that safranal treatment significantly (P < 0.05) increased
the expression of the pro-apoptotic protein Bax and significantly (P < 0.05) decreased
the expression of the anti-apoptotic protein Bcl-2 compared to HCC group. The
Bax/Bcl-2 ratio favored the apoptotic effect of safranal (P < 0.05) in DEN-induced rat
liver tumors (Figure 14). Interestingly, the apoptotic effect of safranal was more
evident when administered alone compared to where both safranal and sorafenib, were
administered or when sorafenib alone was used. To further investigate the apoptotic
effect of safranal, western blot analysis showed that pro-caspase-9, pro-caspase-3, and
PARP results confirmed caspase cascade activation and PARP cleavage, where the
expression of pro-caspases-9 & 3 and whole PARP were significantly decreased
compared to HCC group after treatments with safranal (P < 0.01, P < 0.001, P < 0.001,
respectively) and with both safranal + sorafenib (P < 0.01, P < 0.01, P < 0.001,
respectively) (Figure 15). These results further support the pro-apoptotic effect of
safranal on drug-induced neoplasia.
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Chapter 4: Discussion
4.1 Safranal Restores Liver Function by Reducing ALT and AST
Three main biological processes are carried out in the liver; biochemical
metabolism, bilirubin transport, and immune defense. Aminotransferases like ALT
and AST are enzymes that are responsible for amino group transfer. AST is found in
the cytoplasm and mitochondria of the liver cells, also in cardiac and skeletal muscles.
ALT on the other hand is specifically found in the cytoplasm of liver cells. Any injury
in the liver leads to an elevation of these aminotransferases (Lui, 2018).
Saffron has been shown to restore normal levels of liver enzymes (ALT) thus
restoring liver function (Amin et al., 2011). Similar data has been reported with
sorafenib in DEN-induced liver cancer in Sprague Dawley rats. Sorafenib decreased
ALT an AST levels in the treated livers and retained normal functions of the liver (Lv
et al., 2017). In the present study, serum activities of ALT (P < 0.01), and AST were
increased in HCC group comparing to the control group, which indicates liver damage.
As the results show in (Table 1); treatment with safranal decreased the elevation of
ALT comparing to HCC group (P < 0.01) with a higher efficiency of safranal alone
and the synergic group (HCC + safranal + sorafenib) over sorafenib alone (P < 0.05).
This highlights the efficiency of safranal and its potential in combination therapy.
Since ALT and AST increase in liver injury, the results show that safranal significantly
restores liver function. The insignificant change of AST can be explained as ALT is a
more diagnostic enzyme found exclusively in the liver, while AST is not just found in
the liver, but also in the muscles. AST is also cleared from the liver twice as fast as
ALT, therefore ALT level is increased more than AST after liver injury (Lui, 2018).
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4.2 Safranal has Anti-tumor and Anti-proliferative Activities on DEN Induced
Rat Liver Tumors
4.2.1 Histology
The biopsy taken from the patients’ livers for examination is important for
diagnosis of liver diseases. It often helps to unravel the cause of a demonstrated
damage, or abnormality that have not been reported with other examinations. Any
changes in the normal morphology of the liver found by clinical examination could be
an indication of serious liver lesion (Hübscher, 2015). Histological examination of
DEN-induced (HCC group) showed loss of hexagonal lobular architecture, abnormal
proliferation, loss of the single cell plate arrangement, and nodular neoplastic
transformation that indicate the formation of hepatic neoplasia. similar nuclear
pleomorphism and hyperchromatism were reported elsewhere (Hamza et al., 2018).
Treatment with safranal alone or in combination with sorafenib seem to enhance the
restoration of the normal architecture of the liver in DEN-treated groups.
4.2.2 Reticulin Staining
Connective tissue is a group of cells surrounded by extracellular substances.
These extracellular substances contain fibers; reticular fibers are a network of thin and
delicate type III collagen. In liver tissue, hepatocytes are surrounded by reticular fibers
that provide support and exchange of substances between the cells and blood vessels
(Slomianka, 2009). As reticular fibers network is important for hepatocytes support,
attention was drawn to reticulin staining to investigate changes in reticular fibers in
the liver to identify liver damage. Thioacetamide was used to induce liver fibrosis in
rats and degraded reticular fibers suggesting that breakage of hepatic reticular fibers is
associated with liver damage (Wen et al., 2016).
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Another study investigated metastasis of oral squamous cell carcinoma to
lymph nodes by examining reticular fibers, where in tumor metastasis they formed
thinner and separate strands while in the control they formed thick and bundled
reticular fibers (Yinti et al., 2015). Reticulin staining in human HCC also shows
abnormal reticular structure that surrounds cancerous hepatic cells. Previous reports
revealed that reticulin staining is the most accurate marker for HCC, and the
degradation of reticular fibers supports the diagnosis of HCC (Singhi et al., 2012; Yao
et al., 2013).
Consistent with those studies, present microscopic analysis (Figure 9) showed
that liver tissue of control group showed a uniformed network of reticular fibers
surrounding the hepatic cells. In the experimental groups, DEN-treated livers showed
abnormal, broken reticular fibers that surrounded the cancerous cells indicating that
DEN caused HCC. Whereas in the drug treated groups, the reticulin fibers have
retained their normal morphology being uniformed with less breakage and smaller
lesions comparing to HCC animals. Treatments with safranal (HCC + safranal) and
with both safranal and sorafenib (HCC + safranal + sorafenib) showed more intact
bundles of reticulin fibers, and smaller lesions compared to their counterparts in livers
of animals treated with sorafenib alone (HCC + sorafenib).
4.2.3 Safranal has Anti-proliferative Effect on DEN Induced Rat Liver Tumors
PCNA is highly expressed in dividing cells in the S phase. PCNA plays an
important role in DNA replication, DNA repair and in controlling the cell cycle. Its
structure is best described as a sliding clamp, that stabilizes polymerases during DNA
synthesis. It acts as a signal for proliferation, and if absent, DNA replication is
inhibited, and cells opt for apoptosis.
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Studies also suggest that in case of DNA damage, PCNA recruits special
proteins such as polymerase δ and ligase to the site of damage, and resynthesizes DNA
(Juríková et al., 2016). In cancer research, the first markers checked are proliferation
markers where they increase dramatically in tumors. In a study of non-small cell lung
cancer, results showed elevation in PCNA, and it was related to tumor metastasis as
well, and its elevation inhibited apoptosis (Wang et al., 2018). In another study,
zebrafishes were exposed to DEN which caused liver abnormalities, and PCNA
expression was also elevated (Machado et al., 2014). In this study, western blotting
analysis (Figure 10) showed that PCNA was significantly increased in DEN induced
livers comparing to controls (P < 0.01), while treatments with safranal and with both
safranal and sorafenib downregulated PCNA.
4.3 Western Blotting
4.3.1 Safranal Induces G2/M Cell Cycle Arrest
Living organisms grow and reproduce to survive and maintain their own
characteristics; the same is true for cells. Cells grow and divide into two daughter cells
that are identical to their mother cells. For cells to divide, they must go through the
cell cycle that includes four main phases; G1, S, G2, and M. During these phases the
cell grows and DNA replicates in preparation for ultimate cell division. Checkpoints
are present to ensure that all the cellular materials and DNA are readily available
before division can start. For everything to go smoothly, the cell cycle has its own
control system. This control system is present at different phases, G1/S, G2/M, and at
the M phase. G1/S checkpoint checks that the cell is ready to go for DNA replication,
G2/M checkpoint prepares the cell to go to cell division, and the M phase checkpoint
insures that sister chromatids are ready to separate at the anaphase.
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If checkpoints sense any defect, whether within the cell or outside the cell, they
will halt the next step until such defect is repaired. The main components in the control
system of the cell cycle are the cyclin-dependent kinases (Cdks) and cyclins. Cdks are
kinases that transfer phosphate to regulate the activity of their substrate proteins.
Cyclins, on the other hand, are proteins that are needed to activate Cdks and form a
cyclin-cyclin dependent kinase complex. Cyclin-Cdks are the cell cycle checkpoints.
Cdks are present throughout the cell cycle in the same concentration, whereas cyclins’
concentration varies depending on which phase is the cell at, and each phase has its
own cyclins (Nair & van Staden, 2018).
Cyclin B and Cdk1 are involved in the last step which the cell goes through,
cell division. Cyclin B attaches to Cdk1, yet it is still inactive. Two kinases are
involved in the next step, Wee1, which adds an inhibitory phosphate, and CAK (Cdkactivating kinase), which adds an activating phosphate. To have an active cyclin BCdk1 complex, another enzyme, Cdc25, a phosphatase, removes the inhibitory
phosphate that was added by Wee1, and the resulting complex of cyclin B-Cdk1 is
active, and the cell is ready to divide (Figure 16) (Gardino & Yaffe, 2011).

Figure 16: Cyclin B1-Cdk1 activation
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The important role of Cdks and cyclins in cell cycle made them imperative
targets for cancer therapy, especially that their weak control of the cell cycle is linked
to cancer. Liu and colleagues (2007) suggested that nitrogen-containing flavonoids are
good candidates for inhibiting CDK1/Cyclin B and consequently has led to the
inhibition of cancer cells in vitro (Liu et al., 2007). Plant-derived compounds from
Appendicula reflexa have been also reported to lead to CDK1/Cyclin B inhibition
(Apel et al., 2012). In addition to CDKs and cyclins and thanks to the important role
of Cdc25B in the cell cycle as well by activating the cyclin-Cdk complex, a recent
study showed that microRNA-152 inhibited Cdc25B in human endometrial cancer
cells which induced G2/M phase arrest (Xie et al, 2018). Cdc25B was also reported to
be inhibited by using thiadiazole amides and their derivatives which helped in halting
the cell cycle (Li et al., 2014).
In the current study, western blot results for Cdk1, cyclin B1, Cdc25B (Figure
11), and their quantification (Figure 12), showed significant upregulation of all
assessed markers in HCC animals comparing to control animals (P < 0.01, P < 0.01,
P < 0.05, respectively). Livers of animal groups treated with safranal alone and with
both safranal and sorafenib showed significant (P < 0.001) downregulations as
compared to HCC animals. These results show that safranal targets the cell cycle arrest
at the G2/M phase, blocks cell division suggesting a great potential of future utilization
of safranal as a novel combination/therapy against HCC. Similar results have recently
been reported where safranal caused G2/M cell cycle arrest in HepG2 cells (Al-Hrout
et al., 2018).
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4.3.2 Safranal Induces Apoptosis
Life and death are the normal cycle of life in order to keep balance. In the body,
a group of cells forming a tissue needs to die and reproduce in a matter that keeps the
tissue size uniformed. The growth of tissue should be balanced by the forming of new
cells and the removal of old cells. Cells also die if they sense a harmful invasion, or
DNA damage. Certain cellular mechanisms control this balance between cell death
and cell proliferation to avoid any tumor formation. Programmed cell death (apoptosis)
is mainly triggered by caspases, which are typically inactive in healthy cells, and are
activated upon their cleavage during apoptosis. There are two classes of caspases:
initiators and executioners. When the cell undergoes apoptosis, initiators get activated
first, activating executioners in return, which eventually activates proteases and
nucleases to undergo apoptosis. Two pathways are used by the cell to undergo
apoptosis: intrinsic and extrinsic (Bi et al., 2018). This study will focus on the intrinsic
pathway.
Any cellular stress such as DNA damage, triggers the intrinsic apoptotic
pathway which starts in mitochondria. The released cytochrome c from the
mitochondria binds to a protein called apoptotic protease activating factor-1 (Apaf1)
forming an apoptosome. This apoptosome activates the initiator caspase-9, which
activates the executioner caspase-3, the main apoptosis protein. Cytochrome c release
must be regulated to ensure that cells do not undergo apoptosis all the time, this
regulation occurs by Bcl-2 and Bax proteins. Bcl-2 and Bax bind together in normal
cases, but when an apoptotic signal is received, Bcl-2 breaks loose from Bax which
leads to forming holes in the mitochondria allowing cytochrome c to be released
(Figure 17) (Li et al., 2013).
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Figure 17: Intrinsic, mitochondrial, pathway of apoptosis

PARP is also an important protein that its inhibition regulates apoptosis. PARP
regulates DNA repair and stability. During DNA replication, some errors could occur
breaking the single strand of the growing DNA. The cell senses this error and sends
PARP to seal this ssDNA breakage. In apoptosis, the activation of caspase-3 cleaves
PARP leading to a broken DNA then the whole DNA collapses and the cell goes to
apoptosis (Chaitanya et al., 2010).
Cancer however, usually finds its way to escape apoptosis to survive and even
spread. Studies have focused on the caspase cascade for cancer therapy. Saffron has
been shown to induce apoptosis in lung cancer through the caspase-3 cascade in a dose
and time dependent manner (Liu et al., 2014). DEN induced HCC in rats treated with
melatonin showed a significant increase in active caspases and cleaved PARP, along
with Bax/Bcl-2 ratio in treated rats which resulted in tumor shrinkage via apoptosis
(Moreira et al., 2015). In addition, HCC rats treated with cape gooseberry juice led to
an increase in apoptosis via Bax/Bcl-2 and cleaved caspase-3 upregulation (Hassan et
al., 2017).
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The role of caspase-9 & 3 and bcl-2 was also studied in eosinophil apoptosis
in humans, where the activation of CD30 lead to apoptosis via caspase-3 activation
and bcl-2 inhibition (Lee et al., 2017). Another study examined PARP by inducing
apoptosis via death receptor, CD95. Results showed that activating caspase-3 resulted
in PARP cleavage and mediated apoptotic cell death (Los et al., 2002).
In the present study, western blot analysis (Figure 13, Figure 14, Figure 15),
showed that the intrinsic apoptotic pathway is activated by safranal via activating Bcl2/Bax and caspase-9 & 3 followed by PARP cleavage. The first focus was on the proapoptotic protein Bax and anti-apoptotic protein Bcl-2. The present results showed that
safranal treatment significantly increased the expression of Bax (P < 0.05) and
decreased the expression of Bcl-2 (P < 0.05) as compared to HCC animals.
Subsequently, the Bax/Bcl-2 ratio favored the apoptotic effect of safranal in DENinduced rat liver tumors (P < 0.05). Interestingly, the apoptotic effect of safranal was
stronger when treated alone compared to the combined treatment and was stronger
than sorafenib alone. The apoptotic effect of safranal was further confirmed by
determining the expression of apoptotic markers, caspase-9, caspase-3, and PARP.
Western blot analysis showed that the proportions of pro-caspase-9 and pro-caspase-3
were significantly (P < 0.01, P < 0.001, respectively) decreased as a result of caspase
cascade activation and similarly there was a significant decrease in whole PARP (P <
0.001) compared to HCC group and compared to treatment with sorafenib alone (P <
0.05). These results mark the apoptotic fate of tumor cells. Interestingly, safranal
seemed to help sorafenib-induced PARP cleavage in animal group treated with both
safranal and sorafenib.
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Chapter 5: Conclusion
The novelty of this research stems from the use of a bioactive compound of a
natural source that has been traditionally used as a popular spice and showing how it
may carry the potential to be a novel therapy of liver cancer.
In vivo HCC model was successfully induced in male Wistar rats, then treated
with sorafenib alone, safranal alone, and with both safranal + sorafenib. Data analysis
showed the efficiency of safranal as a drug and an adjuvant in restoring liver function.
Presented results also showed safranal’s inhibitory role of cell cycle, and its proapoptotic capacity suggesting safranal’s high potential as a novel anti-cancer drug.
Further investigations are underway to unravel the molecular mechanisms of
safranal, particularly, in ER stress, UPR activation and DNA repair pathways. At the
present stage, this study could soon be translated to benefit cancer patients as it
convincingly argues for the advantage of safely using safranal/saffron as an adjuvant
therapy.
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